Texas Retina Dallas Research Team Recognized for Highest Site Enrollment Globally in Geographic Atrophy Clinical Trial
Under the leadership of Principal Investigator Dr. Ashkan M. Abbey, the Texas Retina Dallas research team was recently named the top enroller for Part I of the DFI18231 study, which is evaluating
read more
Dr. Coors Treats First Patient in DAYBREAK Clinical Trial of Intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer for Wet AMD
Texas Retina’s Lori E. Coors, MD, recently enrolled and treated the first patient in the Phase III DAYBREAK trial evaluating an intravitreal tarcocimab tedromer and tabirafusp tedromer compared with intravitreal aflibercept in
read more
Dr. Abbey Doses First Patient in Phase III LUGANO Clinical Trial of Duravyu for Wet AMD
Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, recently dosed the first patient in the Phase III LUGANO clinical trial of Duravyu (formerly EYP-1901) for the treatment of
read more
Dr. Abbey Presented Key Results of DAVIO 2 Clinical Trial for Wet AMD at Retina World Congress
At the recently held 2024 Retina World Congress Meeting, Texas Retina’s Dallas Director of Clinical Research Ashkan M. Abbey, MD, presented topline results from the DAVIO 2 clinical trial investigating EYP-1901 (Duravyu),
read more Dr. Abbey Contributes to Real-world Study of Faricimab for Neovascular Age-related Macular Degeneration
The TRUCKEE study is a real-world, collaborative effort to investigate the efficacy, durability, and safety of a monoclonal antibody treatment called faricimab in patients suffering from neovascular age-related macular degeneration (nAMD) in
read more